BioSpace News Archive

XOMA Corporation announced it has earned a $9 million milestone related to the U.S. Food and Drug Administration’s approval of Day One Biopharmaceuticals’ New Drug Application for OJEMDA™ for the treatment of patients 6 months of age and older with relapsed or refractory pediatric low-grade glioma harboring a BRAF fusion or rearrangement, or BRAF V600 mutation.

Cerevance, a company focused on developing precision novel therapeutics for central nervous system diseases, announced an initial closing of its Series B-1 Extension financing round that will add $47 million to the $51 million previously raised bringing the total Series B-1 raise to $98 million.

Collegium Pharmaceutical, Inc. today announced that it will report first quarter 2024 financial results after the market closes on Thursday, May 9, 2024.

Achieve Life Sciences, Inc. (Nasdaq: ACHV) today announced it will report its first quarter 2024 financial results and provide an update on the cytisinicline development program on Thursday, May 9, 2024, at 4:30 PM EDT.

Sensus Healthcare, Inc. reminds investors that management will hold a conference call on Thursday, May 9, 2024 at 4:30 p.m. Eastern time to discuss the financial results for the first quarter of 2024.

Aquestive Therapeutics, Inc. today announced that it will report results for the first quarter ended March 31, 2024 and provide an update on recent developments in its business after market close on Tuesday, May 7, 2024.

Candel Therapeutics, Inc. today announced that two abstracts were accepted for presentation at the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting taking place May 31 to June 4, 2024, in Chicago, IL.

BioStem Technologies Inc. today announced that it will present at the Planet MicroCap Showcase: VEGAS 2024 held at the Paris Hotel & Casino, in Las Vegas, NV., from April 30 - May 2 2024.

Aligos Therapeutics, Inc. wishes to express its condolences on the recent passing of Stephen A. Harrison, MD., Col, FAASLD, who served as a trusted advisor and the Principal Investigator for the Company’s ongoing Phase 2a HERALD study in metabolic dysfunction-associated steatohepatitis subjects.

Integer Holdings Corporation announced results for the three months ended March 29, 2024.